Conformis and Sites Medical are forming a nonexclusive development and supply agreement, according to a Jan. 21 news release.
The companies will work together to incorporate Sites Medical's OsteoSync Ti technology into Conformis' cementless total knee replacement products going forward, the release said. OsteoSync Ti technology is a porous titanium bone ingrowth material and has been used in more than 50,000 procedures since it was introduced for clinical use in 2014.
"We are excited to be partnering with Conformis, a company that has brought a high degree of innovation to the joint replacement field," Greg Stalcup, president and CEO of Sites Medical said in the release. "We look forward to working with the Conformis team to combine our respective technologies to deliver new generations of high performance, cost effective, and OR-efficient products to the market."